![share_log](https://pubimg.futunn.com/20210416029208795164fdb91e7.jpg?imageMogr2/thumbnail/76x76!/ignore-error/1/format/webp)
Recursion Pharmaceuticals | 10-Q: Q1 2024 Earnings Report
Recursion Pharmaceuticals | 10-Q: Q1 2024 Earnings Report
Recursion Pharmaceuticals | 10-Q:2024財年一季報
牛牛AI助理已提取核心訊息
Recursion Pharmaceuticals, a clinical-stage TechBio company, reported significant business developments and financial performance in its latest quarterly report. The company received a substantial $150.0 million upfront payment from its collaboration with Roche in January 2022, with potential for additional milestone payments and fees that could exceed $250.0 million for accepted Phenomaps. Roche may also initiate up to 40 programs, each potentially yielding over $300.0 million for Recursion. Revenue recognized in the quarter ending March 31, 2024, was primarily from the upfront payment, reducing the unearned revenue balance from the previous year. Recursion reported a net loss of $91.4 million for the quarter, compared to $65.3 million in the same period last year, and an accumulated deficit of $1.1 billion as of March 31, 2024. Despite the losses, the company has cash...Show More
Recursion Pharmaceuticals, a clinical-stage TechBio company, reported significant business developments and financial performance in its latest quarterly report. The company received a substantial $150.0 million upfront payment from its collaboration with Roche in January 2022, with potential for additional milestone payments and fees that could exceed $250.0 million for accepted Phenomaps. Roche may also initiate up to 40 programs, each potentially yielding over $300.0 million for Recursion. Revenue recognized in the quarter ending March 31, 2024, was primarily from the upfront payment, reducing the unearned revenue balance from the previous year. Recursion reported a net loss of $91.4 million for the quarter, compared to $65.3 million in the same period last year, and an accumulated deficit of $1.1 billion as of March 31, 2024. Despite the losses, the company has cash and cash equivalents of $296.3 million and expects these funds to cover operations for at least the next twelve months. Recursion's pipeline includes several clinical and preclinical programs, with Phase 2 data for its CCM trial expected in Q3 2024 and Phase 2 safety and preliminary efficacy data for its NF2 trial anticipated in Q4 2024. The company is also expanding its computational capabilities with the near completion of BioHive-2, a supercomputer designed with NVIDIA, and is advancing a whole-genome transcriptomics map. Strategic partnerships, such as with Helix for genomic data, continue to be a focus, and the company plans to use its raised capital for operating and investing activities, including platform research, drug discovery, and clinical development.
臨床階段TechBio公司Recursion Pharmaceuticals在其最新季度報告中報告了顯着的業務發展和財務業績。該公司與羅氏的合作使其在2022年1月獲得了大額的1.5億美元的預付款,並有可能獲得超過2.5億美元的里程碑付款和費用,以出售被接受的Phenomaps的情況下。羅氏還可以啓動多達40個計劃,每個計劃潛在帶來超過3億美元的回報給Recursion。截至2024年3月31日的本季度營業收入主要來自於預付款,並減少了未獲得收入餘額。Recursion報告了本季度的淨虧損爲9140萬美元,相比去年同期的6530萬美元,累積虧損爲11億美元,截至2024年3月31日。儘管存在虧...展開全部
臨床階段TechBio公司Recursion Pharmaceuticals在其最新季度報告中報告了顯着的業務發展和財務業績。該公司與羅氏的合作使其在2022年1月獲得了大額的1.5億美元的預付款,並有可能獲得超過2.5億美元的里程碑付款和費用,以出售被接受的Phenomaps的情況下。羅氏還可以啓動多達40個計劃,每個計劃潛在帶來超過3億美元的回報給Recursion。截至2024年3月31日的本季度營業收入主要來自於預付款,並減少了未獲得收入餘額。Recursion報告了本季度的淨虧損爲9140萬美元,相比去年同期的6530萬美元,累積虧損爲11億美元,截至2024年3月31日。儘管存在虧損,但該公司擁有296.3億美元的現金和現金等價物,並預計這些基金可以覆蓋至少未來12個月的運營。Recursion的管道包括多個臨床和臨床前的項目,其CCm試驗的2期數據預計在2024年第三季度公佈,其NF2試驗的2期安全性和初步療效數據預計在2024年第四季度公佈。該公司還在擴展其與NVIDIA共同設計的超級計算機BioHive-2的計算能力,並正在推進全基因組轉錄組圖譜。戰略伙伴關係,例如與Helix進行基因組數據合作,仍然是重點,並且該公司計劃使用籌集到的資本進行經營和投資活動,包括平台研究,藥物發現和臨床開發。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了